[go: up one dir, main page]

MX9405290A - Derivados de piperazina y sales de los mismos, proceso para su preparaciony medicamentos que los contienen. - Google Patents

Derivados de piperazina y sales de los mismos, proceso para su preparaciony medicamentos que los contienen.

Info

Publication number
MX9405290A
MX9405290A MX9405290A MX9405290A MX9405290A MX 9405290 A MX9405290 A MX 9405290A MX 9405290 A MX9405290 A MX 9405290A MX 9405290 A MX9405290 A MX 9405290A MX 9405290 A MX9405290 A MX 9405290A
Authority
MX
Mexico
Prior art keywords
group
piperazine
medicines
derivatives
salts
Prior art date
Application number
MX9405290A
Other languages
English (en)
Inventor
Hitoshi Tone
Masatoshi Morisue
Katsumi Tamura
Toshiki Miyazaki
Yoshimasa Nakano
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX9405290A publication Critical patent/MX9405290A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un objetivo de la presente invención es proporcionar un derivado depiperazina y sal del mismo que tiene efecto inhibitorio contra radicalessuperóxido (O2-). El derivado de piperazina de la presente invención estárepresentado por la fórmula general: ( en donde R1 es un grupo alquiloinferior; R2 es un grupo fenilalquilo inferior que puede tener de 1 a 3sustituyentes, en el anillo fenilo, seleccionados del grupo que consistede un grupo hidroxilo, un grupo fenilalcoxi inferior, un grupo alquiloinferior, un grupo alcoxi inferior y un átomo de halógeno; R3 es un átomode hidrógeno, un grupo alquilo inferior o un grupo fenilalquilo inferior;y R4 es un grupo hidroxilo, un grupo fenilalcoxi inferior o un grupotetrahidropiraniloxi).
MX9405290A 1993-07-13 1994-07-12 Derivados de piperazina y sales de los mismos, proceso para su preparaciony medicamentos que los contienen. MX9405290A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5172780A JPH0725858A (ja) 1993-07-13 1993-07-13 ピペラジン誘導体

Publications (1)

Publication Number Publication Date
MX9405290A true MX9405290A (es) 1995-01-31

Family

ID=15948218

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9405290A MX9405290A (es) 1993-07-13 1994-07-12 Derivados de piperazina y sales de los mismos, proceso para su preparaciony medicamentos que los contienen.

Country Status (10)

Country Link
US (1) US5607934A (es)
EP (1) EP0659182A1 (es)
JP (1) JPH0725858A (es)
KR (1) KR950703554A (es)
CN (1) CN1112364A (es)
AU (1) AU676584B2 (es)
CA (1) CA2143203A1 (es)
MX (1) MX9405290A (es)
PH (1) PH31162A (es)
WO (1) WO1995002593A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4810043B2 (ja) * 2000-01-18 2011-11-09 ネリアス・ファーマシュティカルズ・インコーポレーテッド 細胞分裂阻害剤及びその製造方法
YU96502A (sh) * 2000-06-21 2006-01-16 F. Hoffmann-La Roche Ag. Derivati benzotiazola
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
DK1529044T5 (da) * 2002-08-02 2008-04-21 Nereus Pharmaceuticals Inc Dehydrophenylahistiner og analoger deraf og syntesen af dehydrophenylahistiner og analoger deraf
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
EP1964835A1 (en) * 2007-02-28 2008-09-03 Centre National de la Recherche Scientifique Derivatives of psammaplin A, a method for their synthesis and their use for the prevention or treatment of cancer
WO2010011927A1 (en) * 2008-07-25 2010-01-28 Noventis, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
CA2806208C (en) 2010-07-22 2018-02-13 Zishan Haroon Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution
CN101935306B (zh) * 2010-07-22 2013-12-25 沈阳药科大学 二酮哌嗪类衍生物及其应用
KR102623404B1 (ko) 2015-03-06 2024-01-11 비욘드스프링 파마수티컬스, 인코포레이티드. 뇌 종양 치료 방법
BR112017018954A2 (pt) 2015-03-06 2018-05-15 Beyondspring Pharmaceuticals, Inc. uso de forma mutante de proteína ras e método para tratar câncer
ES2910035T3 (es) 2015-07-13 2022-05-11 Beyondspring Pharmaceuticals Inc Composiciones de plinabulina
CN108778267A (zh) 2016-02-08 2018-11-09 万春药业公司 包含妥卡雷琐或其类似物的组合物
MX389200B (es) 2016-06-06 2025-03-20 Beyondspring Pharmaceuticals Inc Composición y método para reducir la neutropenia.
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
MX2019009020A (es) 2017-02-01 2019-11-12 Beyondspring Pharmaceuticals Inc Metodo para reducir la neutropenia.
CN110054619A (zh) * 2018-01-18 2019-07-26 西北农林科技大学 新型二酮哌嗪类组蛋白去乙酰化酶抑制剂
AU2019212118A1 (en) 2018-01-24 2020-09-03 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
US20240197723A1 (en) 2021-04-09 2024-06-20 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009380A1 (fr) * 1989-02-10 1990-08-23 Otsuka Pharmaceutical Co., Ltd. Derives d'indole, leur preparation et medicament les contenant destine a la prevention et au traitement de la nephrite

Also Published As

Publication number Publication date
US5607934A (en) 1997-03-04
KR950703554A (ko) 1995-09-20
JPH0725858A (ja) 1995-01-27
EP0659182A1 (en) 1995-06-28
CA2143203A1 (en) 1995-01-26
AU7083294A (en) 1995-02-13
PH31162A (en) 1998-03-20
AU676584B2 (en) 1997-03-13
WO1995002593A1 (en) 1995-01-26
CN1112364A (zh) 1995-11-22

Similar Documents

Publication Publication Date Title
MX9405290A (es) Derivados de piperazina y sales de los mismos, proceso para su preparaciony medicamentos que los contienen.
MX9206847A (es) Derivados de indolpirrolcarbazol, proceso para su preparacion y medicamento que los contiene
ATE169008T1 (de) 3,5-dioxo-(2h,4h)-1,2,4-triazinderivate ihre herstellung und verwendung als medikament
ES473074A1 (es) Un procedimiento para la preparacion de derivados de tieno- tiacina
ATE12492T1 (de) Aryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
ES2180477T3 (es) Compuestos intermedios para la preparacion de derivados de oxazolidindiona y tiazolidindiona.
AR245447A1 (es) Procedimiento para preparar derivados de 2,4-diamino-5-(biciclo-sustituido)metilpirimidinas.
BR9612099A (pt) Processo para preparar um composto derivado de piperidina, regioisÈmero, processo para preparar um regioisÈmero, derivado de ácido 4-( alfa,alfa, di-substuìdo) toluico e 4- (alfa, alfa-di-não substitìdo) toluico.
AR012603A1 (es) Inhibidor de proteasa, composicion farmaceutica que lo comprende y el uso del mismo para la fabricacion de un medicamento; e intermediarios de sintesis
AR002690A1 (es) Derivado de bencimidazol o sales del mismo, composicion farmaceutica, agente inmunosupresor y agente antiinflamatorio que lo contienen yprocedimientos para preparar dicho derivado.
ES2036562T3 (es) Un procedimiento para produccion de un derivado de pirrolidinamida.
ES8706608A1 (es) Un procedimiento para preparar derivados de arilciclobutilalquilamina
MX9306227A (es) Nuevos derivados de taxano, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2070238T3 (es) Emulsion de lipidos que contiene un analogo de prostaglandina.
ATE40358T1 (de) 2,3-dihydrobenzofuran-derivate, mehrere verfahren zu ihrer herstellung und sie enthaltende arzneimittel.
AR009266A1 (es) Un derivado de aciloamino alquenilen-amida, un proceso para su preparacion y una composicion farmaceutica que lo comprende
ES2038166T3 (es) Procedimiento para preparar un derivado de indenotiazol.
AR041376A1 (es) Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia
ATE239711T1 (de) Neue allythiopyridazinderivate und verfahren zu ihrer herstellung
ES2063117T3 (es) Derivados del tieno(2,3-d)acepina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
DK0806413T3 (da) 2-substituerede viatmin D3-derivater
CO4520266A1 (es) Derivado de 1,3-oxazin-4-ona, el herbicida que lo contiene y los productos intermedios para prepararlo
ES461796A1 (es) Un procedimiento para la preparacion de nuevos derivados de tiofeno.
ES2086442T3 (es) Derivados de fluoroetilcamptotecina.
SE9001269L (sv) 2-substituerade n,n'-ditrimetoxbensoylpiperaziner, en framstaellningsmetod foer dessa samt terapeutiska kompositioner som innehaaller dem